share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Mahatme Sandesh

SEC announcement ·  May 31 04:34
Summary by Futu AI
Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.
Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.